ulodesine
Pre-clinical- Indications
- Relapsed leukemia after allogeneic stem cell transplantation
Company intelligence / Profile preview
Laevoroc Immunology AG
Hünenberg, Zug, Switzerlandlaevoroc.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
Developing LR 09 (Ulodesine), a PNP inhibitor, for treatment of leukemia relapse after stem cell transplantation. Received FDA Orphan Drug Designation in February 2023.
- Therapeutic areas
- OncologyHematology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Research collaborations with UCLA and Fred Hutchinson Cancer Center in Seattle
Beyond the preview
Go deeper on Laevoroc Immunology AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Laevoroc Immunology AG.